Category Archives: Genetic Engineering

A Type 1 diabetes patient is the first patient to be cured of the disease with a new treatment, a clinical trial report claims, paving the way for those who also hope to beat it.

Per The New York Times, the clinical trial by Vertex Pharmaceuticals has been testing a treatment for decades. Thirty years and $50 million later, the first patient is cured.

Brian Shelton, now 64, got his first cell infusion of stem cells, which act like insulin-producing pancreas cells that his body lacked.

His body now controls its insulin and blood sugar levels automatically. Its a whole new life, Shelton said in The New York Times report. Its like a miracle.

It is a remarkable result, Dr. Peter Butler, a diabetes expert at the University of California, Los Angeles, said in the report. To be able to reverse diabetes by giving them back the cells they are missing is comparable to the miracle when insulin was first available 100 years ago.

The study will continue for five years, involving 17 people with a severe case of Type 1 diabetes. This will give 9 million people who are suffering from this disease a chance at a major change in their life.

According to the Centers for Disease Control and Prevention, for Type 1 diabetes, the pancreas doesnt make enough insulin. Without insulin, blood sugar can build up in the bloodstream, instead of entering cells to be used for energy.

Currently, the cell infusion treatment requires cells that are within a class of immunosuppressants that depress the immune system, said professor Douglas Melton, whose lab pioneered the science behind the therapy, per The Harvard Gazette

Without the immunosuppressants, these cells would be rejected by the body. We want to find a way to make cells by genetic engineering that are not recognized as foreign, he said.

Dr. Scott Summers, chairman of Nutrition and Integrative Physiology at the University of Utah. thinks a lot of work is left to be done and he views this study with caution.

At this point, we have only read about the results in one patient. The clinical trial is still ongoing, and the full set of results arent anticipated for several years. The paper hasnt been peer-reviewed. A heated discussion is actually ongoing amongst scientists about whether it is ethical or appropriate to publicize data so early in the study, he told the Deseret News.

The fact that it is a biotechnology company permits a marketing aspect that cannot be ignored. Its odd for a press release to occur so early in the study, he added.

Summers also has some suspicion regarding Melton. Despite being an excellent scientist, he reacted to a huge paper five years ago. His group allegedly discovered a hormone that could stimulate the proliferation of insulin cells. But those findings could not be replicated.

So, Melton did what any ethical scientist would do he retracted the paper.

This is a good reminder that findings need to be rigorously evaluated and replicated by multiple groups before carving them in stone, said Summers.

Despite these concerns, Im excited, he added. This discovery could have a transformative impact on our understanding and treatment of this insidious disease.

See original here:
New testing finds that one man might be the first cured of Type 1 diabetes. Whats next for the research? - Deseret News

Topline data show SAB-176 achieved statistically significant reductions in viral load and clinical symptoms and it appeared safe and well-tolerated

Second clinical proof of concept achieved by DiversitAbplatform in past two months

Positive clinical results confirm that SABs fully-human polyclonal antibodies can be broadly neutralizing to both known and unknown viral variantsa valuable feature when addressing rapidly mutating pathogens

SAB plans to further evaluate SAB-176 in a Phase 2 influenza clinical trial slated to beginin 2Q 2022

SIOUX FALLS, S.D., Dec. 01, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that SAB-176, its investigational therapeutic for the treatment of seasonal influenza, achieved statistically significant (p = 0.026) reductions in viral load and clinical signs and symptoms compared to placebo in a Phase 2a challenge study. In the study, SAB-176 appeared to be safe and well-tolerated. SAB-176 is a quadrivalent fully human polyclonal antibody therapeutic candidate designed for the treatment of moderate to severe Type A and B seasonal influenza viruses.

We are highly encouraged by these topline results showing that treatment with SAB-176 achieved statistical significance in reducing influenza viral load and clinical signs and symptoms in treated subjects, despite the small size of this first Phase 2 study. These data suggest that SAB-176 has the potential to be an effective treatment for this prevalent, highly-mutating virus that resurfaces annually and is a major source of hospitalizations and deaths, said Tom Luke, MD, Chief Medical Officer of SAB Biotherapeutics. These trial results support advancing SAB-176 as a potential treatment for seasonal influenza through further clinical studies, and we look forward to sharing additional data as it becomes available.

These positive efficacy data for SAB-176 represent the second clinical proof of concept achieved by our DiversitAbplatform in the past two months, said Eddie J. Sullivan, PhD, Co-Founder, President, and Chief Executive Officer of SAB Biotherapeutics. In September our investigational COVID-19 therapy SAB-185 met the pre-defined efficacy goal for advancement from Phase 2 to Phase 3 in the NIH-sponsored ACTIV-2 trial. These back-to-back clinical successes for our first two pipeline products give us confidence that the DiversitAb platform is clinically validated. They reinforce our commitment to advancing this unique platform, with its demonstrated ability to rapidly generate therapeutic candidates for highly mutating pathogen targets with ongoing resurgence and pandemic potential, including influenza and COVID-19.

About SAB-176 Challenge StudyThe Phase 2a challenge study, initiated in June 2021, was a randomized, double-blind, placebo-controlled study evaluating the safety and treatment efficacy of SAB-176 in 60 healthy adults challenged with a pandemic influenza virus strain (pH1N1). Participants were randomized to receive either SAB-176 (25 mg/kg dose) or placebo and were intranasally inoculated with pandemic H1N1 (2009/California) virus, and nasopharyngeal swabs were taken 8 days after inoculation.

The primary endpoint of the study was reduction of the nasopharyngeal viral load of subjects treated with SAB-176 (expressed as area under the curve, or AUC) compared to those receiving placebo over an 8-day timepoint as measured by qRT-PCR. SAB-176 met the primary endpoint of significantly reducing patient pH1N1 influenza viral load in the treated subjects (p = 0.026, one sided).

A secondary endpoint of the challenge study was reduction of clinical flu signs and symptoms in the subjects receiving active treatment (n=8) compared to placebo controls (n=12) for those who had signs and symptoms. SAB-176 achieved statistical significance in meeting the secondary endpoint at Day 4 (p = 0.013, one sided) in symptomatic patients. Additional analyses of secondary endpoint data are underway.

In this study SAB-176 also appeared to be safe and well tolerated. No SAB-176-related serious adverse events (SAEs) were observed, and most adverse events were mild to moderate. Based on these positive efficacy and safety results, SAB plans to further evaluate SAB-176 in advanced clinical trials.

One remarkable aspect of these results is that SABs Tc Bovine were not immunized to the specific influenza virus strain that was used in the challenge study, added Christoph Bausch, PhD, Chief Scientific Officer of SAB Biotherapeutics. Nonetheless, the statistically significant reduction in virus load and symptoms that were achieved confirm that SAB-176 demonstrated high cross reactivity to this pandemic strain. This reinforces a unique and timely feature of our DiversitAbplatformthe diversity of the human antibodies it produces gives our therapeutics the potential to be broadly neutralizing to both known and unknown viral variantsa very valuable feature when addressing rapidly mutating pathogens.

For more information on the Phase 2a clinical trial, visit clinicaltrials.gov (Identifier NCT04850898).

About SAB-176SAB-176 is a multivalent, broadly neutralizing fully-human polyclonal antibody therapeutic candidate in development for the treatment or prevention of severe influenza. The novel, specifically-targeted therapeutic leverages the natural human biological immune response to specifically bind to Type A and Type B influenza viruses. Like vaccines, it can be modified to address annual strain changes, when needed, to maintain broader coverage as the flu virus mutates. Preclinical data suggests that SAB-176 offers broad protection against diverse influenza strains.

SABs novel DiversitAb immunotherapy platform enables the production of large amounts of targeted, highly potent human polyclonal antibodies. The platform leverages transchromosomic cattle (Tc Bovine) that have been genetically designed to generate fully human antibodies (immunoglobulin G) rather than bovine antibodies, in response to inoculation with an immunogen.

To develop and produce SAB-176, Tc Bovine were hyperimmunized with a quadrivalent antigen, including a number of influenza strains. Within a brief period of time, the Tc Bovine generated significant amounts of fully-human antibodies to combat the virus, driving titers beyond the levels known to be protective. Plasma was collected (in a similar manner as from human plasma donors), then purified to isolate the antibodies that comprise the therapeutic treatment.

About Seasonal InfluenzaInfluenza virus infection is one of the most common infectious diseases and can lead to severe illness, and death. According to the US Centers for Disease Control (CDC), on average about 8% of the US population gets sick each flu season and between 12,000 and 61,000 infected Americans die, depending on the severity of the flu season. In 2019-2020, considered a moderate flu season, 38 million people in the US became ill with the flu, 18 million saw a healthcare provider for treatment, 400,000 were hospitalized and an estimated 22,000 died. Globally, there are between 2.5 and 5 million influenza-related hospitalizations per year. The CDC recommends an annual flu shot for almost everyone over the age of six months, but each year less than half the population is vaccinated. In addition, because influenza viruses are highly mutating, the vaccines have varying levels of protection in any year, but rarely exceed 50% protection. Young children, the elderly, immune-compromised individuals, and patients with chronic health conditions are especially at risk of poor outcomes from influenza, yet there are few approved therapies for the treatment of influenza.

About SAB Biotherapeutics, Inc.SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine that produce fully-human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SABs versatile DiversitAb platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs. For more information on SAB, visit: https://www.sabbiotherapeutics.com/ and follow @SABBantibody on Twitter.

Contacts:Melissa Ullerich+1 605-679-4609mullerich@sabbiotherapeutics.com

Courtney Turiano (investors)Stern IR+1 212-698-8687Courtney.Turiano@sternir.com

Forward-Looking Statements Certain statements made herein that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as believe, may, will, estimate, continue, anticipate, intend, expect, should, would, plan, predict, potential, seem, seek, future, outlook and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events. These statements are based on the current expectations of SAB and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict, will differ from assumption and are beyond the control of SAB. Forward-looking statements are subject to various risks and uncertainties, including, among others, those related to the COVID-19 pandemic; SABs ability achieve successful results for its product candidates, the availability of financing, and trends affecting SABs financial condition or results of operations. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are described under the sections entitled "Risk Factors" in the Company's proxy statement/prospectus filed with the Securities and Exchange Commission (the "SEC") on September 24, 2021. Such factors may be updated from time to time in SABs periodic filings with the SEC, which are accessible on the SECs website at http://www.sec.gov. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. The forward-looking statements speak only as of the date of this press release, and SAB expressly disclaims any obligation or undertaking to publicly update or review any forward-looking statement.

Here is the original post:
SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus - BioSpace

There is much media hype around the fourth industrial revolution (4IR) and what it will hail for social and economic development. It is defined as a fusion of advances in artificial intelligence (AI), robotics, the internet of things (IOT), genetic engineering, quantum computing, and more.

One thing is clear: the world is not on the brink of a technological revolution that will fundamentally alter the way we live, work and relate to one another but rather we are in the thick of it.

This is borne out by research, with one Statista study forecasting the number of IOT devices worldwide will triple from 8.74 billion in 2020, to more than 25.4 billion IOT devices by 2030. The same study noted that in 2020, the highest number of IOT devices was in China, at 3.17 billion devices.

IOT devices are used in all types of industry verticals and consumer markets, with the consumer segment accounting for around 60% of all IOT connected devices in 2020. This share is projected to stay at this level over the next 10 years.

The most important use cases for IOT devices in the consumer segment are internet and media devices such as smartphones, where the number of IOT devices is forecast to grow to more than eight billion by 2030. Other use cases with more than one billion IOT devices by 2030 are connected (autonomous) vehicles, IT infrastructure, asset tracking plus monitoring and smart grid applications.

Unpacking 4IR, IOT and technology spending

The first industrial revolution used water and steam power to mechanise production, while the second used electric power to create mass production, and the third utilised electronics and information technology to automate production.

Now the 4IR has taken the innovations of the third and built on them to create the digital revolution that has been occurring since the middle of the last century. It is said to be characterised by a fusion of technologies that is blurring the lines between the physical, digital and biological spheres.

Today's transformations represent not merely a prolongation of the third industrial revolution, but rather the arrival of a fourth and distinct one.

The speed of current breakthroughs has no historical precedent, as when compared with previous industrial revolutions, the fourth is evolving at an exponential pace.

The speed of current breakthroughs has no historical precedent, as when compared with previous industrial revolutions, the fourth is evolving at an exponential pace. Moreover, it is disrupting almost every industry in every country, with the breadth and depth of these changes heralding the transformation of entire systems of production, management and governance.

So, what exactly is the 4IR? According to the World Economic Forum (WEF), it is a new era that builds and extends the impact of digitisation in new and unanticipated ways. In other words, it is the convergence of technology, digital, data and artificial intelligence that brings about new and unanticipated ways of working, living and engaging, such as in a metaverse.

It can also be said to be about the internet of everything from fitness trackers to the smart thermostats used both commercially and in homes, to the fleet-management solutions that tell us when our packages will arrive IOT is now embedded in the lives of consumers, as well as the operations of enterprises and governments.

IOT is the holy grail of innovation in the 21st Century, as predicted by everyone from McKinsey to Gartner. It largely started with the invention of the cloud and has since accelerated with the advances in both communication technology as well as new engineering innovation of IOT devices.

In a world where many companies suffer revenue declines, it is clear that IT spending is accelerating ahead of revenue expectations. According to Gartner, technology spending has entered a new build budget phase, with worldwide IT spending projected to total $4.2 trillion by the end of 2021, which represents an increase of 8.6% over 2020.

The research team goes on to note that CIOs are looking for partners that can think past the digital sprints of 2020 and be more intentional in their digital transformation efforts in 2021.

Boards and CEOs are much more willing to invest in technology that has a clear tie to business outcomes, and less so for everything else. For example, the IT services segment is among the top three highest growth areas for 2021, primarily due to a boost in infrastructure-as-a-service spending that supports mission-critical workloads and avoids high on-premises costs. The IT services segment is forecast to total $1.2 trillion in 2021, an increase of 9.8% over 2020.

However, IOT is not a panacea for all business ills according to McKinsey, IOT has faced headwinds related to change management, cost, talent and cyber security, particularly in enterprises.

With this level of investment there are unquestionably opportunities for South African businesses capable of identifying and capitalising on them. IOT start-ups need to focus on finding the right strategic partnerships that are based on mutually acceptable values of trust and respect.

In my next article, I will expand on the state of SA's readiness for the 4IR.

View original post here:
In the thick of the opportunity revolution - ITWeb

Medicinal Plant

According to a survey report recently prepared by a team of scientists led by Dr. Saurabh Panday from Indian Institute of Technology, Roorkee, as many as 32 rare species of angiospermic plants found in the Matanhel Forest Area, Jhajjar, Haryana are on the verge of extinction, posing a serious threat to biodiversity.

Biodiversity reflects the health of the planet and has a direct impact on every aspect of our lives. To put it simply, reduced biodiversity means that millions of people will face a future in which food supplies will be more vulnerable to pests and disease, and freshwater will be in irregular or short supply.

Medicinal plants are used in the treatment of cancer, respiratory and cardiac diseases, ulcers, liver and kidney infections, and other diseases. The report will be submitted to the state government soon in order for further action to be taken to protect these plants.

"Overexploitation of natural resources, urbanization, habitat loss, extreme hunting, pollution, and climate change are the primary causes of these 32 rare plants' extinction.

These plants include indigofera cordifolia, physalis angulata, senna occidentalis, senegalia catechu, Tinospora cordifolia, and Sida Cordifolia, among others," said Dr. Panday, a former principal investigator at the International Centre for Genetic Engineering and Biotechnology in New Delhi.

He claimed that the leaves, stems, roots, seeds, and barks of all 32 species from 21 families had been used for medicinal purposes since ancient times.

He added that there was an urgent need to take critical steps for their protection as well as for dealing with climate change, which was detrimental to the ecosystem and biodiversity.

"The threat to biodiversity affects not only the flora and fauna but also the environmental conditions," said Dr. Kavita Saini, an entomologist and prominent member of the survey team. Butterflies are considered a bio-indicator of the ecosystem, but our survey found that three prominent butterfly species- blue argus, danaus chrysippus, and papillo pollutes- are also on the verge of extinction due to destruction of their milkweed habitats caused by urbanization, insecticide use, and climate change.

View original post here:
Biodiversity Loss: 32 Medicinal Plants are on the verge of Extinction, as per a survey - Krishi Jagran

during the forecast period. The growth of the genome editing/genome engineering market is expected to be driven by the rise in government funding and growth in the number of genomics projects, increased application areas of genomics, and the introduction of CRISPR-Cas9 for genome engineering.

New York, Nov. 25, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Genome Editing/Genome Engineering Market by Technology, Product & Service, Application, End user - Global Forecast to 2026" - https://www.reportlinker.com/p05220258/?utm_source=GNW

The services segment accounted for the highest growth rate in the genome editing/genome engineering market, by product & service, during the forecast periodIn 2020, the services segment accounted for the highest growth rate.The genomic editing/genome engineering services market is segmented into sequencing services; data analysis; bioinformatics services; and other services, such as informatics, clean up, gene expression, and DNA synthesis services.

Most companies in the services sector offer all these services.Although the services segment represents a major part of the market, some end users have in-house sequencing and bioinformatics capabilities.

Service providers possess highly advanced and multiple sequencing platforms and make use of high-quality consumables/kits. They also have multiple sequencing platforms, which enables these service providers to choose the most appropriate system to solve the scientific challenges of their customers and promptly deliver high-quality sequencing at a low cost.

The CRISPR segment accounted for the largest share of the application segment, by technology, in the genome editing/genome engineeringIn 2020, the CRISPR technology accounted for the largest share.Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is a revolutionary tool used to edit genes in a way that resembles traditional GMO techniques.

The use of the Cas9 enzymes differentiates CRISPR from other forms of genetic modification.The ease of use associated with CRISPR technology gives it a significant advantage over ZFN and TALEN, especially in generating a large set of vectors to target numerous sites or even genome-wide libraries.

Another potential advantage of CRISPR is its ability to use multiple guide RNA parallelly to target multiple sites simultaneously in the same cell. This makes it easier to mutate multiple genes at once or engineer precise deletions in a genomic region.

Asia Pacific: The fastest-growing region in the genome editing/genome engineering marketThe genome editing/genome engineering market is segmented into North America, Europe, Asia Pacific, Latin America (LATAM) and Middle East and Africa (MEA). Increasing government support, and developing R&D infrastructure Increasing investments in research and rising number of applications of gene synthesis for genetic engineering of cells and tissues of organisms are the major factors fueling the growth of the genome editing/genome engineering market in the Asia Pacific region.

The primary interviews conducted for this report can be categorized as follows: By Respondent: Supply Side- 70% and Demand Side 30% By Designation: C-level - 55%, D-level - 20%, and Others - 25% By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%

List of Companies Profiled in the Report: Thermo Fisher Scientific (US) Merck KGaA (Germany) GenScript China) Sangamo Therapeutics (US) Lonza (Switzerland) Editas medicine (US) CRISPR Therapeutics Tecan Life sciences (Switzerland) Precision biosciences (US) Agilent technologies (Switzerland) PerkinElmer (US) Cellectis SA (France) Intellia Therapeutics (US) Bluebird Bio (US) Regeneron Pharmaceuticals (US) Synthego (US) Vigene Biosciences (US) Beam Therapeutics (US) Integrated DNA Technologies (US) New England Biolabs (US) Origene Technologies (US) Transposagen Biopharmaceuticals (US) Creative Biogene (US) Recombinetics (US) Caribou Biosciences (US)

Research Coverage:This report provides a detailed picture of the genome editing/genome engineering market.It aims at estimating the size and future growth potential of the market across different segments such as the product, application, end user and region.

The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall genome editing/genome engineering market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.

This report will enable stakeholders to understand the markets pulse and provide them with information on the key market drivers, restraints, challenges, trends, and opportunities.Read the full report: https://www.reportlinker.com/p05220258/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

View original post here:
The global genome editing/genome engineering market is expected to reach USD 11.7 billion by 2026 from USD 5.1 billion in 2021, at a CAGR of 18.2% -...

If humans are to live on Mars or the moon one day, well need to be able to construct buildings to live, sleep, eat, and work in space. The way to do that, space agencies have said, is to 3D-print habitats or their components. But hauling enough of the Earth-derived materials used for most 3D printing from our planet to another celestial body isnt a feasible option.

Biology could solve that problem, says Neel Joshi, associate professor of chemistry and chemical biology at Northeastern. And Joshis team may have devised just the technology for the job: a 3D-printable material that is alive.

Like a tree has cells embedded within it and it goes from a seed to a tree by assimilating resources from its surroundings in order to enact these structure-building programs, what we want to do is a similar thing, but where we provide those programs in the form of DNA that we write and genetic engineering, Joshi says.

The researchers have figured out how to program the bacterium Escherichia coli, also known as E. coli, to produce an entirely biological ink which can be used to 3D-print solid structures. That microbial ink, which is described in a paper published Tuesday in the journal Nature Communications, has yet to be tested on a cosmic scale, but the scientists have used the gelatinous material to print small shapes, such as a circle, a square, and a cone. They have also successfully programmed it to build materials with specified attributes with other applications that could be useful in medicine.

Neel Joshi, associate professor of chemistry and chemical biology, works on programmable microbial ink for 3D printing of living materials, in the Mugar Life Sciences building. Photos by Matthew Modoono/Northeastern University

We want to use living cells, microbes, as factories to make useful materials, says Avinash Manjula-Basavanna, a postdoctoral fellow in Joshis laboratory and co-lead author on the new paper. The idea, he says, is to harness the properties that are unique to the materials that make up living things for a spectrum of purposes, ranging from therapeutic to industrial.

Think about it as a platform for building many different things, not just bricks for building buildings or construction, Joshi says. He explains the work by comparing it to the way a polymer chemist considers how to devise plastic materials that can serve distinct purposes. Some plastics are hard and retain their shape, while others are stretchy and soft.

Biology is able to do similar things, Joshi says. Think about the difference between hair, which is flexible, and horns on a deer or a rhino or something. Theyre made of similar materials, but they have very different functions. Biology has figured out how to tune those mechanical properties using a limited set of building blocks.

The particular natural building block the scientists are taking advantage of is a protein produced by the bacterium E. coli. The material, called Curli fibers, is produced by the bacterial cells as they attach to a surface and to one another to form a community. The same properties that make the Curli fibers a sort of glue for the bacteria also make it an attractive material for microbial engineers like Joshi and his colleagues.

The researchers 3D-printed small shapes using the microbial ink that they developed from the bacterium Escherichia coli, also known as E. coli. Image courtesy of Duraj-Thatte et al., Nature Communications

To make the microbial link, the scientists started by culturing genetically engineered E. coli in a flask. They fed the bacteria nutrients so that they would multiply, and as they divided they would produce the desired polymers, the Curli fibers. Then, the researchers filtered out the gelatinous polymers and fed that material into a 3D printing apparatus as the microbial ink.

Microbes have been used to make the ink for 3D printing before, but, Joshi and Manjula-Basavanna say, what sets this microbial ink apart is that it is not blended with anything else. Their gel is entirely biological.

One of the perks of a truly living material is that it is, in fact, alive, Manjula-Basavanna says. And that means that it can do what living things can do, such as heal itself, the way skin does. In the right conditions, the cells in the microbial gel could simply make more of itself.

Its not necessarily always growing, Joshi says. For example, if the cells were left alive in the small cone that the team made from the microbial gel, if you were to take that whole cone and dunk it into some glucose solution, the cells would eat that glucose and they would make more of that fiber and grow the cone into something bigger, he says. There is the option to leverage the fact that there are living cells there. But you can also just kill the cells and use it as an inert material.

While the initial gel is made entirely from genetically engineered E. coli, the researchers also tried mixing the ink with other genetically engineered microbes with the goal of using the 3D-printed materials for specific purposes. Thats how they made a material that could deliver an anticancer drug, which it released when it encountered a specific chemical stimulus. In another experiment, they also programmed another material to trap the toxic chemical Bisphenol A (BPA) when it encountered BPA in the environment.

You could think about taking a bottle cap and printing our material on the inside of it so that if there was BPA around, it would be sucked up by that and not be in your drink, Joshi says.

This study was simply a proof-of-concept endeavor, but Joshi sees this microbial ink as opening a door to all kinds of possibilities for building things with biology.

If there is a way to manufacture in a more sustainable manner, its going to involve using living cells, he says. This is advancing more towards that type of paradigm of building things with living cells.

For media inquiries, please contact Marirose Sartoretto at m.sartoretto@northeastern.edu or 617-373-5718.

See more here:
With this New Technology, 3D Printing Comes to Life Literally. - News @ Northeastern - News@Northeastern

I asked Davey, as well as Elke Mhlberger, another researcher at NEIDL, if they were ever fearful. Once they became comfortable with the pressurized suits, they said, they experienced a kind of joy in the privileges of the work, as well as confidence in containment measures. To Mhlberger, in fact, working in a Level 2 or Level 3 facility feels riskier than being in a Level 4 lab, where the safety protocol is so stringent; the day before she gave birth to her second son, she told me, she spent the morning working with the Ebola virus in a Level 4 lab. Once inside, there are no cellphones, no email, no small talk only the pathogens and the white noise of air swirling around her ears. Its really very relaxing, she said. Her work is focused on the planets most formidable threats, she acknowledged. But it is in many ways an escape from the world itself.

Is that world better off with or without high-containment biolabs? Its a question not easily resolved. The work that goes on inside them involves a nontrivial degree of risk, which is why NEIDL, with its vaults and barricades and bulwarks including its operational protocols resembles a modern-day citadel. Yet no amount of engineering, infrastructural or human, can reduce to zero the chance of bad things coming out of biolabs. On the other hand, without them, we would lack all sorts of treatments for diseases like Covid-19 and Ebola. For now, the world seems to agree that we need these facilities.

Next summer, the C.D.C. will break ground on a new high-containment laboratory complex on its campus in Atlanta. One ambition is to supplement an aging biolab with a five-story, state-of-the-art facility that includes two Level 3 suites and six Level 4 suites. These will be largely dedicated to studying viruses with more fearsome fatality rates: Ebola, Nipah, Marburg, Chapare. Construction will take about three years, followed by a two-year commissioning process to ensure safety expectations are met. The cost has been reported to be at least $350 million a significant jump from the $280 million (adjusted for inflation) that built the NEIDL facilities. Melissa Pearce, who will oversee the new lab, told me that she and her C.D.C. colleagues have toured North American facilities in recent years to survey current best practices and design ideas.

Ideas that are too new wont necessarily be adopted. When youre designing a Biosafety Level 4, the thought of using new technology tends to give you pause, Pearce told me. Its like the first year of a brand-new model of a car you tend to not want to buy that, because there are probably some bugs that need to get worked out. So, many of the improvements in Atlanta are likely to be incremental. Some of the researchers on the planning team believe that the spaces in current Level 4 labs are too narrow, for example, so there will be more room within new suites for workers to move around freely. A new chemical shower off the hallway will allow the staff to sanitize equipment more efficiently.

To talk to people at the C.D.C. is to be struck by how close to the next pandemic they think we might be and how important, should a little-known infectious agent again explode in the general population, the research done on exotic viruses in containment there and elsewhere will be in directing us toward therapies or a cure. Thats the expectation at NEIDL, too, where Mhlberger has recently been working with the Lloviu virus, a relative of Ebola, which was first identified in bats in Eastern Europe 10 years ago. A group in rural Hungary extracts small amounts of blood from local bat colonies, searching for Lloviu. If the virus is present, the group sequences and sends the genetic information to her. She then compares its viral properties with other pathogens to better understand potential dangers. We dont know yet whether it causes disease in humans or not, she said. But if it causes disease, about 200 million people live in the area where these bats roam.

When I asked Joel Montgomery, the head of the viral special pathogens branch at the C.D.C., whether our awareness of new pathogens is a result of improved surveillance or of more viruses having increased opportunities to jump into humans, he seemed to think both factors were responsible. The ability to test new viruses, thanks to nucleic-acid-sequencing capabilities, is far better than it was 10 or 20 years ago. But I think we are interacting with our environment much more now than we have before, and just the sheer number of people on the planet has increased, he said, which also affects population densities. And so were going to see outbreaks epidemics, pandemics happening more frequently. It most certainly will happen.

Our high-containment facilities, moreover, may have to deal with threats hatched in labs as well as what comes from nature. Take, for example, pox diseases. The C.D.C.s campus in Atlanta is home to one of two Level 4 labs left in the world that harbors the live variola virus, which causes smallpox and was declared eradicated globally in 1980. (The other cache is in Russia.) Victoria Olson, a deputy director of lab science and safety at the C.D.C., told me that the lab keeps samples because studies using a live virus could help scientists develop diagnostics, treatments and vaccines should smallpox re-emerge, or should a similar poxvirus appear. Monkey pox, which has caused recent outbreaks in Africa, where it has a fatality rate of 10 percent, is already a serious concern; Alaska pox was just identified in 2015. More alarming, perhaps, is the potential that someone outside the world of known biolabs might cook up a version of a poxvirus, using the tools of genetic engineering. Smallpox had an average case-fatality rate of about 30 percent; Americans have not been immunized against it since 1972. A synthetic smallpox or even a synthetic super smallpox, which could be deadlier than the original is not much of an intellectual leap.

See original here:
You Should Be Afraid of the Next Lab Leak - The New York Times

DUBLIN, Nov. 24, 2021 /PRNewswire/ -- The "Cell Therapy - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. The role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice.

Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.

Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering, and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation, and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.

Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues.

Regulatory and ethical issues involving cell therapy are important and are discussed. The current political debate on the use of stem cells from embryonic sources (hESCs) is also presented. Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations.

The cell-based markets was analyzed for 2020, and projected to 2030. The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair, as well as diabetes mellitus, will be other major markets.

The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 317 of these are profiled in part II of the report along with tabulation of 306 alliances. Of these companies, 171 are involved in stem cells.

Profiles of 73 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 67 Tables and 26 Figures. The bibliography contains 1,200 selected references, which are cited in the text.

Markets and Future Prospects for Cell Therapy

Key Topics Covered:

Part I: Technologies, Ethics & Regulations

Executive Summary

1. Introduction to Cell Therapy

2. Cell Therapy Technologies

3. Stem Cells

4. Clinical Applications of Cell Therapy

5. Cell Therapy for Cardiovascular Disorders

6. Cell Therapy for Cancer

7. Cell Therapy for Neurological Disorders

8. Ethical, Legal and Political Aspects of Cell therapy

9. Safety and Regulatory Aspects of Cell Therapy

Part II: Markets, Companies & Academic Institutions

10. Markets and Future Prospects for Cell Therapy

11. Companies Involved in Cell Therapy

12. Academic Institutions

13. References

For more information about this report visit https://www.researchandmarkets.com/r/lbqs59

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

The rest is here:
Global Cell Therapy Markets Report 2021-2030: Cell Therapy Markets According to Therapeutic Areas, Technologies, & Companies - PRNewswire

The bioeconomy covers all sectors and systems that rely on biological resources (animals, plants, microorganisms, and derived biomass, including organic waste) as well as their functions and principles. It includes and interlinks economic and industrial sectors such as food, health, chemicals, materials, energy and services that use biological resources and processes.

It is anticipated that the world will face increased competition for limited and finite natural resources given a growing population, increasing pressure on our food and health systems, and climate change and associated environmental degradation decimating our primary production systems.

Synthetic biology is an emerging field which applies engineering principles to the design and modification of living systems, thus underpinning and accelerating technological advances with clear potential to provide impact at scale to the global economy. Manufacturers are turning towards this method to efficiently produce high performance, sustainable products.

A recent McKinsey report anticipates applications from this bio revolution could have a direct global impact of up to $4 trillion per year over the next 10-20 years, enabling production of 60% physical inputs to the global economy, and addressing 45% of the worlds current disease burden. However, for synthetic biology applications to reach their full potential, its critical to ensure that access and development of knowledge in this sector, along with the relevant research tools, are distributed in low resource contexts. This can help to avoid the technology being centered solely in advanced, resource rich economies and widening inequalities in the global bioeconomy.

Dr. Jenny Molloy, Senior Research Associate at the Department of Chemical Engineering and Biotechnology, University of Cambridge, studies the role and impact of open approaches to intellectual property for a sustainable and equitable bioeconomy.

Her work focuses on better understanding problems facing researchers accessing biological research tools in low resource contexts, particularly Latin America and Africa. Her team develops innovative technologies for local, distributed manufacturing of enzymes to improve access and build capacity for biological research. The broader aim of her research is to contextualize open source approaches to biotechnology within current narratives of innovation and the bioeconomy policy agenda. She is also a member of the World Economic Forum Global Future Council on Synthetic Biology.

We discussed new developments, challenges, and her ideal scenario for the bioeconomy policy agenda for the next 10 years. Here's what she said:

Realizing that the current system of how we fund, reward, publish and disseminate science, and how we balance public and private interests in technology is quite recent and could be changed.

Originally, I worked on advocacy for open data and open science (which fortunately is now much more mainstream within research culture), and then my introduction specifically to bioeconomy policies came when I worked on genetic modification of dengue mosquitoes for my doctorate. This put me right at the intersection of global health, synthetic biology, and the bioeconomy in a field nested in a complex tangle of ethics, regulation, responsible innovation, and public opinion.

At the same time, I was contributing to projects on open science for development and getting more interested in how to make access to science, innovation, and its benefits truly global. Everything started pointing to the imperative of working to ensure that we collectively build a global bioeconomy that is equitable and economically and environmentally sustainable.

Id say the ability to de novo synthesise DNA at scale and precisely edit it. When I was trying to genetically engineer mosquitoes, constructing DNA modules was laborious and it was really a roll of the dice as to where in the genome that DNA would end up. Having more affordable ways to write as well as read DNA with increased elegance, precision editing of CRISPR has enabled exciting advances to address so many global challenges: from drug discovery to crop improvement.

That is why I find enabling tools and technologies so exciting: they underpin innovation and users will deliver applications that the original developers didnt dream about. A lot of my work focuses on how to ensure that these developments reach all scientists and not only those in high income countries.

I would say the perception and narrative that is strongly embedded in biotechnology at all levels that open source means uncommercialisable.

Unfortunately, this leads to an unwillingness to creatively explore openness as one possibility within a whole range of Intellectual Property (IP) strategies. I wish people knew to ask, What impact do I want to achieve in the world and to what extent can protecting or openly sharing this technology get me there?. Sometimes, youll land back on patenting everything because the promise of a monopoly is required to unlock sufficiently risk tolerant investment. That is OK!

However, the answer is likely more nuanced when your goal is also environmental or social impact or where you have a user community that could contribute back significant innovations or for many other reasons. Teslas patent pledge in 2014 was likely partially because their success depends on public and private investment in infrastructure like charging stations, so while sharing their technology might allow competitors to get to market faster, that could increase the number of electric cars on the road and the interests of electric car drivers and industry. All this nuance gets missed if you dont ask the question.

One of the best sources of knowledge in biotechnology is, perhaps somewhat ironically, published patents! Developing and emerging economies have immense freedom to apply this knowledge commercially as very few biotech patents have been filed in the Global South while many more have expired and entered the public domain.

However, there are major challenges to making that knowledge used and useful, including having enough people skilled in the art and providing an enabling environment - well equipped labs, reliable supply chains, responsive regulation and funding. Open source approaches play an important role here because beyond open licensing they also encourage collaborative development and sharing of know how, which is essential to overcome barriers to building capacity and innovation.

The application of precision medicine to save and improve lives relies on good-quality, easily-accessible data on everything from our DNA to lifestyle and environmental factors. The opposite to a one-size-fits-all healthcare system, it has vast, untapped potential to transform the treatment and prediction of rare diseasesand disease in general.

But there is no global governance framework for such data and no common data portal. This is a problem that contributes to the premature deaths of hundreds of millions of rare-disease patients worldwide.

The World Economic Forums Breaking Barriers to Health Data Governance initiative is focused on creating, testing and growing a framework to support effective and responsible access across borders to sensitive health data for the treatment and diagnosis of rare diseases.

The data will be shared via a federated data system: a decentralized approach that allows different institutions to access each others data without that data ever leaving the organization it originated from. This is done via an application programming interface and strikes a balance between simply pooling data (posing security concerns) and limiting access completely.

The project is a collaboration between entities in the UK (Genomics England), Australia (Australian Genomics Health Alliance), Canada (Genomics4RD), and the US (Intermountain Healthcare).

For example, basic laboratory equipment like incubators are typically no longer protected by IP but you will rarely find full assembly and repair instructions online: open hardware projects provide this and bring together communities of developers and manufacturers to enable local manufacturing. Access to enzymes is an almost ubiquitous challenge in the Global South and while many useful enzymes are now in the public domain, it can be time consuming to find the DNA and protocols to express them.

Open toolkits like the Research in Diagnostics DNA Collection designed by my lab and many collaborators and distributed through the Free Genes project at Stanford provides a ready to go solution that with the correct manufacturing practices, quality management systems and regulatory approvals could also be used for diagnostics kits. Local manufacturing of molecular diagnostics is a possibility we are exploring with collaborators in Cameroon and Ghana, for example through the AfriDx project funded by EDCTP.

A great example of an open project that has already had a direct impact on scientific progress is the Structural Genomics Consortium, a public-private-partnership which has openly released data, materials and research tools for drug discovery against medically relevant human protein structures to academia and industry for around 20 years, resulting in thousands of collaborations and scientific papers and over 1500 protein structures entering the public domain. The leaders of the consortium continue to push the model further, for example launching pharma companies that aim to apply an open approach to drug discovery for rare childhood cancers.

Realizing that the current system of how we fund, reward, publish and disseminate science and how we balance public and private interests in technology is quite recent and could be changed.

My ideal scenario is that the global bioeconomy policy agenda is truly global, so that over the next 10 years countries in the Global South, that host so much of the biodiversity that is fuelling the bioeconomy, are able to shape that agenda, to level up innovation capacities, and to benefit from the bioeconomy on their own terms.

My advice to global leaders and policymakers is to ensure that all countries get a seat at the table and focus on building out more than local or regional policies but also systems for international governance that can adapt to the extraordinary pace of technical and social change in the bioeconomy.

The Global Future Council on Synthetic Biology has focused a lot of our attention on how to embed the values of sustainability, equity, humility and solidarity into the future bioeconomy policy agenda, providing a compass rather than a map, because we think this is important to ensure that synthetic biology is being harnessed to create a world in which we want to live.

Written by

Abhinav Chugh, Acting Content and Partnerships Lead, World Economic Forum

The views expressed in this article are those of the author alone and not the World Economic Forum.

See the rest here:
Synthetic biology can benefit all of us, an expert explains - World Economic Forum

PUNE, India, Nov. 25, 2021 /PRNewswire/ -- According to The Insight Partners study on "Animal Genetics Market to 2027 Global Analysis and Forecast by Animal Genetic Material, Genetic Material and Service" the animal genetics market was valued at US$ 4,778.67 million in 2019 and is projected to reach US$ 7,705.23 million by 2027; it is expected to grow at a CAGR of 6.3% during 20192027. The growth of the market is attributed to the growing preference for animal derived proteins supplements and food products and rising adoption of progressive genetic practices such as artificial insemination (AI) and embryo transfer. However, limited number of skilled professionals in veterinary research and stringent government regulations for animal genetics is expected to hinder the market growth.

The North American region holds the largest market share of this market and is expected to grow in forecasted years. The growth in North America is characterized by the presence of new market players, various product launches and increasing government initiatives.

Get Exclusive Sample Pages of Animal Genetics Market - COVID-19 Impact and Global Analysis with Strategic Insights at https://www.theinsightpartners.com/sample/TIPRE00003517/

Likewise, Mexico is likely to offer attractive business opportunities for livestock genetics. Over the last decades, Mexico's beef, pork, and dairy productions have undergone valuable developments. Mexican generators in the expanding livestock intensive systems are frequently using modern genetic improvement technologies such as artificial insemination and embryo transfers.

In North America, the US is the largest market for animal genetics market. Livestock groups provide consumers with different products and services, including meat, milk, eggs, fiber, and draught power. The genetic variation within livestock communities produces the raw material for evolving through natural selection in answer to changing conditions and human-managed genetic improvement plans. As per the Food and Agriculture Organization (FAO), animal genetics is one of the livestock development support. It is a wide field, ranging from characterization to conservation to genetic development. According to the National Institute of Food and Agriculture (NIFA), there have been dramatic improvements in animal production yields and efficiencies. Therefore, the ever-increasing demand for dietary protein in the United States has been observed. These demands are achieved by one the best Animal breeding is one strategy by which these improvements may be performed. NIFA, with the help of scientists from universities and research organizations and food animal industries, provides national leadership and funding opportunities to conduct basic, applied, and integrated research to increase knowledge of animal genetics and genomics.

The COVID-19 outbreak has disturbed various trades and businesses across the world. The incidence of corona virus or COVID 19 has not yet been registered the animals. Also, there is no evidence that companion animals are the prime source of the spreading epidemic in humans. However, various studies have been conducted to check the spread of disease from animals to humans. In many cases, zoonotic diseases were found in humans due to interaction with animals. Therefore, government bodies are taking more precautions and safety measures to prevent the spread of corona virus in the animals. The measures are widely carried out for companion animals as they frequently come in contact with their owners. Also, it is essential to report the cases to a veterinary authority. For instance, in the region, to report the cases of detection of COVID-19 is done to OIE through WAHIS, in accordance with the OIE Terrestrial Animal Health Code as an emerging disease.

The OIE is actively working by providing assistance to research for their on-going research and other implications of COVID-19 for animal health and veterinary public health. The assistance is also providing risk assessment, risk management, and risk communication. Also, the OIE has put in place an Incident Coordination System to coordinate these activities. In addition, OIE is also working with the Wildlife Working Group and other partners to develop a long-term work program. The aims are to provide better understandings, dynamics, and risks around wildlife trade and consumption. Also, it aims to develop strategies to reduce the risk of future spillover events.

Download the Latest COVID-19 Analysis on Animal Genetics Market Growth Research Report at https://www.theinsightpartners.com/covid-analysis-sample/TIPRE00003517/

Additionally, various product and service launches have been initiated, which is helping the US market to grow. For instance, The Veterinary Genetics Laboratory (VGL) at the UC Davis School of Veterinary Medicine has launched an updated and advanced website along with several new tests for veterinary community. As the VGL is one of the foremost genetic testing laboratories in the world, the new site and tests will bring yet another level of global impact to the top-ranked veterinary school. Thus, the consistent support for combating addiction in the country undertaken by various organizations likely to augment the growth of animal genetics market during the forecast years.

The Asia Pacific region is expected to be the fastest-growing region among all other regions. The growth of the market in the region is majorly due to countries like China, India and Japan, which drives the major consumption of animal derived products. Moreover, growing preference for animal derived proteins supplements and food products, and rising adoption of progressive genetic practices such as artificial insemination (AI) and embryo transfer are also likely to contribute to market growth. On the other hand, significant investment by government in various breeding programs is supporting the growth of market. For instance, the central and local governments have invested more than RMB 5 billion to build breeding or multiplier farms and conservation farms for breed improvement programs and the building of centers for testing the quality of breeding stock, semen, and embryos.

Based on product, the animal genetics market is segmented poultry, porcine, bovine, canine, and others. The porcine segment accounted for more than 35.84% of the market share in 2019. In terms of genetic material, the animal genetics market is segmented into semen, and embryo. The embryo segment held the largest share of the market in 2019. In terms of service, the animal genetics market is segmented into DNA typing, genetic trait tests, genetic disease tests, and others.The DNA typing segment held the largest share of the market in 2019.

Rising Adoption of Progressive Genetic Practices Such as Artificial Insemination (AI) and Embryo Transfer in Animal Genetics Market:

Growing focus on developing superior animal breeds using genetic engineering to obtain high reproduction rates for large-scale production of modified breeds is expected to drive animal genetics market during the forecast period. Animal genetics emphasizes the inheritance and genetic variations in wild and domestic animals. This science is used at a commercial level for services such as testing genetic disorders, screening genetic traits, and typing DNA. For identifying genetic hybridizations, animal genetics uses various genetic practices, such as artificial insemination, embryo transfer, and cytological studies. Moreover, artificial insemination (AI) can reduce various risks involved in animal breeding and disease transmission. It is found that female offspring cattle born through artificial insemination yield more milk than normal offspring. Additionally, the use of antibiotic-containing semen extensors is effective in preventing bacterial infectious diseases. Therefore, the entire AI process is considered hygienic than natural mating.

The market players are focusing on partnerships, collaboration, and acquisitions to develop genetically modified breeds and maintain their market share. For instance, in August 2020, Cogent and AB Europe collaborated to launch a novel sexed semen service for sheep producers in the UK. In May 2018, Recombinetics entered into partnership agreement with SEMEX for the implementation of a precision breeding program, which is expected to improve animal health and well-being through hornless dairy cattle genetics. According to the Brazilian Association of Artificial Insemination, the number of commercialized doses of semen increased from 7 million in 2003 to ~14 million in 2017. Thus, rising adoption of genetic practices will support the market growth in coming years.

Inquire before Buying (Animal Genetics Market Research): https://www.theinsightpartners.com/inquiry/TIPRE00003517/

Market: Segmental Overview

In terms of product, porcine segment is anticipated to register the highest CAGR during the forecast period. Growing production of porcine and increase in pork consumption is likely to favor the growth of the market. Pork is the most consumed meat across the globe. In the US, pork production generates $23.4 billion output per year. Additionally, 26% that is around 2.2 million metric tons of pork and its products are exported to other countries. Despite of the challenges such as tariffs, labor and disease risks, the pork industry in US is still growing with around 66,000 sows in 2019. Also, developments by the major pork producers in the country is likely to grow the pork production industry. For instance, in 2017, 123-year-old Clemens Food Group partnered with 12 independent hog farmers to establish a new packing plant in Michigan. Thus, growing pork production industry is likely to favor market growth. In terms of genetic material, the animal genetics market is segmented into semen, and embryo. The embryo segment held the largest share of the market in 2019. In terms of service, the animal genetics market is segmented into DNA typing, genetic trait tests, genetic disease tests, and others.The DNA typing segment held the largest share of the market in 2019.

Animal Genetics Market: Competition Landscape and Key Developments

Neogen Corporation, Genus, Groupe Grimaud, Topigs Norsvin, Zoetis Services Llc, Hendrix Genetics Bv, Envigo, Vetgen, Animal Genetics Inc, Alta Genetics Inc. and among others are among the key companies operating in the animal genetics market. These players are focusing on the expansion and diversification of their market presence and the acquisition of a new customer base, thereby tapping prevailing business opportunities.

Order a Copy of Animal Genetics Market Shares, Strategies and Forecasts 2021-2028 Research Report athttps://www.theinsightpartners.com/buy/TIPRE00003517/

Browse Related Reports and Get Sample copy

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person:Sameer JoshiE-mail: [emailprotected]Phone:+1-646-491-9876Press Release: https://www.theinsightpartners.com/pr/animal-genetics-market More Research:https://www.einpresswire.com/newsroom/the_insight_partners/

SOURCE The Insight Partners

Originally posted here:
Animal Genetics Market Worth ($7705.23 Mn by 2027) by (6.3% CAGR) with Impact of Coronavirus Outbreak and Global Analysis & Forecast by The...